Download the presentation here: PDF
Download the presentation here: PDF
Download the presentation here: PDF
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
TRPV1: Not Dead Yet<br />
78<br />
Potential Opportunities:<br />
• Development by different routes of administration (e.g., topical).<br />
• Development of short half-life antagonists.<br />
• Development of antipyretic + TRPV1 antagonist combination.<br />
• Development of TRPV1 antagonists in primary indications (e.g., OA).<br />
• One compound previously in development (GSK’s SB-705498) did<br />
not induce hyper<strong>the</strong>rmia in patients treated with 400mg of <strong>the</strong> drug.<br />
Amgen <strong>presentation</strong>, Arrowhead Pain Conference 2008<br />
© Defined Health, 2009<br />
Pain Insight Briefing